Core binding factor acute myeloid leukaemia and c-KIT mutations

Riera,Ludovica; Marmont,Filippo; Toppino,Daniela; Frairia,Chiara; Sismondi,Francesca; Audisio,Ernesta; Di Bello,Cristiana; D'Ardia,Stefano; Di Celle,Paola  Francia; Messa,Emanuela; Inghirami,Giorgio; Vitolo,Umberto; Pich,Achille

doi:10.3892/or.2013.2328

Core binding factor acute myeloid leukaemia and c-KIT mutations

Authors:
- Ludovica Riera
- Filippo Marmont
- Daniela Toppino
- Chiara Frairia
- Francesca Sismondi
- Ernesta Audisio
- Cristiana Di Bello
- Stefano D'Ardia
- Paola Francia Di Celle
- Emanuela Messa
- Giorgio Inghirami
- Umberto Vitolo
- Achille Pich
View Affiliations

Affiliations: Department of Molecular Biotechnology and Health Sciences, Section of Pathology, University of Turin, Turin, Italy, Department of Haematology, Azienda Ospedaliera Città della Salute e della Scienza, Turin, Italy, Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy
Published online on: March 5, 2013 https://doi.org/10.3892/or.2013.2328
Pages: 1867-1872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Core binding factor (CBF) acute myeloid leukaemia (AML) represents 5-8% of all AMLs and has a relatively favourable prognosis. However, activating c-KIT mutations are reported to be associated with higher risk of relapse and shorter survival. To verify the incidence and prognostic value of c-KIT mutations in CBF AML, we retrospectively analysed bone marrow samples of 23 consecutive adult patients with de novo CBF AML [14 inv(16) and 9 t(8;21)] treated at a single institution from 2000 to 2011. All patients received standard induction chemotherapy with cytarabine, idarubicin and etoposide; 13 underwent allogeneic stem cell transplantation. c-KIT mutations in exons 8, 9, 10, 11, 13, 14 and 17 were assessed by PCR amplification in combination with direct sequencing. c-KIT mutations (3 in exon 10 and 4 in exon 17) were detected in 7/23 (30.4%) patients, 3 with t(8;21) and 4 with inv(16). No difference in c-KIT mutation status was observed between cases with inv(16) or t(8;21) alone and cases with additional cytogenetic abnormalities. No association between gender, age, white blood cell and platelet count, peripheral blood and bone marrow blast cells at diagnosis, achievement of complete remission, cytogenetic risk groups and Wilms tumour gene 1 (WT1) levels was found. On the contrary, lactate dehydrogenase (LDH) values were higher in mutated than in non-mutated patients (p=0.01). Overall survival (OS) rates were longer in CBF compared to the other types of AML and disease-free survival (DFS) was longer in inv(16) than in t(8;21) AML. OS and DFS were similar in mutated and non-mutated CBF AML patients. Our results confirm a better prognosis for CBF AML than all other AML categories, and for inv(16) than t(8;21) AML. However, no prognostic value for c-KIT mutational status was found in our series. The association between LDH levels and c-KIT mutation would indicate a more active proliferation for mutated CBF AML.

View Figures

View References

1	Speck NA and Gilliland DG: Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2:502–513. 2002. View Article : Google Scholar : PubMed/NCBI
2	Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J and Bloomfield CD: Acute myeloid leukaemia with recurrent genetic abnormalities. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J and Vardiman JW: 4th edition. IARC Press; Lyon: pp. 110–112. 2008
3	Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA and Bloomfield CD: Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B Study. Blood. 90:4532–4538. 1997.PubMed/NCBI
4	Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC and Mayer RJ: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58:4173–4179. 1998.PubMed/NCBI
5	Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 92:2322–2333. 1998.PubMed/NCBI
6	Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA and Bloomfield CD; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 24:3904–3911. 2006. View Article : Google Scholar : PubMed/NCBI
7	Park SH, Chi HS, Min SK, Park BG, Jang S and Park CJ: Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res. 35:1376–1383. 2011. View Article : Google Scholar : PubMed/NCBI
8	Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA and Bloomfield CD: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 90:1643–1648. 1997.PubMed/NCBI
9	Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL and Dombret H; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l’Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 102:462–469. 2003. View Article : Google Scholar : PubMed/NCBI
10	Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H and Heil G: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 22:3741–3750. 2004.PubMed/NCBI
11	Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA and Bloomfield CD: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 23:5705–5717. 2005. View Article : Google Scholar : PubMed/NCBI
12	Marková J, Marková J, Trnková Z, Michková P, Maaloufová J, Starý J, Cetkovský P and Schwarz J: Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma. 50:1448–1460. 2009.PubMed/NCBI
13	Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH and Miettinen M: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol. 157:1091–1095. 2000. View Article : Google Scholar : PubMed/NCBI
14	Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD and Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:8118–8121. 2001.PubMed/NCBI
15	Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E and Pilotti S: c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res. 13:2369–2377. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kottaridis PD, Gale RE and Linch DC: Flt3 mutations and leukaemia. Br J Haematol. 122:523–538. 2003. View Article : Google Scholar : PubMed/NCBI
17	Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M and Ehninger G: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 107:4011–4020. 2006. View Article : Google Scholar : PubMed/NCBI
18	Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B and Valk PJ: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 106:3747–3754. 2005. View Article : Google Scholar
19	Gulley ML, Shea TC and Fedoriw Y: Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia (Review). J Mol Diagn. 12:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sangle NA and Perkins SL: Core-binding factor acute myeloid leukemia. Arch Pathol Lab Med. 135:1504–1509. 2011. View Article : Google Scholar : PubMed/NCBI
21	Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR and Estey EH: The clinical spectrum of adult acute myeloid leukaemia associated with corebinding factor translocations. Br J Haematol. 135:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T and Hiddemann W: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 101:64–70. 2003. View Article : Google Scholar
23	Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N and Aul C: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 19:2223–2231. 2005. View Article : Google Scholar
24	Spoo AC, Lübbert M, Wierda WG and Burger JA: CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 109:786–791. 2007. View Article : Google Scholar : PubMed/NCBI
25	Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H and Preudhomme C; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 20:965–970. 2006. View Article : Google Scholar : PubMed/NCBI
26	Dombret H, Preudhomme C and Boissel N: Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol. 16:92–97. 2009. View Article : Google Scholar : PubMed/NCBI